(Palo Alto, CA – November 1, 2013)  – Galileo Analytics Co-Founder Anna McCollister-Slipp will speak at the upcoming DiabetesMine Innovation Summit at the Stanford Medical School on November 16.

McCollister-Slipp will speak about the need for patients to lead the way to drive innovation in a range of important areas, such as medical device innovation, data integration, device interoperability and usability, all of which will help improve our ability to understand and manage chronic illnesses, such as diabetes.

In its third year, the annual DiabeteMine Innovation Summit brings together a range of top-level stakeholders in the diabetes community to focus attention on the need for speeding the rate of innovation in medical devices.

In addition to McCollister-Slipp, the summit will feature speakers from the FDA, West Health Institute and TidePool, a new non-profit formed by diabetes parents and patients, which develops patient-focused diabetes data applications. Afternoon panels will feature executives from Aetna, Capital Blue Cross/Blue Shield, Humana and Kaiser Permanente discussing the role of payers and insurers in promoting innovation in diabetes devices and care.

For further information about the DiabetesMine Innovation Summit and to see the full agenda, click here.


About Admin

Anna McCollister-Slipp is co-founder of Galileo Analytics, a Visual Data Exploration and advanced data analytics company focused on democratizing access to and understanding of complex health data. In addition, she is the Chief Advocate for Participatory Research at the Scripps Translational Science Institute, where she is charged with bringing the expertise of patients, caregivers and community physicians into the design of health research. Anna’s passion for innovation in health data research is rooted in her personal experiences living with type 1 diabetes. As an entrepreneur and advocate, she speaks frequently about the promise of digital health, the imperative for patient data access and the need for improved outcomes measures for chronic disease. Anna serves on a number of government and private committees and boards aimed at promoting innovative ways to better understand, manage and treat complex health conditions, such as diabetes.

%d bloggers like this: